Showing results (781-790 of 6,300) with videos related to

Sort By:
Pageof 630
Diabetes, Obesity & Metabolism|November 13, 2020
Use of dipeptidyl peptidase-4 inhibitors and risk of splanchnic vein thrombosis: A Danish nationwide new-user active comparator cohort studyAnton Pottegård, Lars Christian Lund, Daniel Pilsgaard Henriksen, et al.
Diabetes, Obesity & Metabolism|November 13, 2020
Cardiovascular outcomes and safety with linagliptin, a dipeptidyl peptidase-4 inhibitor, compared with the sulphonylurea glimepiride in older people with type 2 diabetes: A subgroup analysis of the randomized CAROLINA trialMark A Espeland, Richard E Pratley, Julio Rosenstock, et al.
Diabetes, Obesity & Metabolism|September 7, 2020
Patient-reported outcomes in a study of human regular U-500 insulin delivered by continuous subcutaneous insulin infusion or multiple daily injections in patients with type 2 diabetesJieling Chen, Ludi Fan, Xiaomei Peng, et al.
Diabetes, Obesity & Metabolism|September 7, 2020
Lower cardiorenal risk with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational studyKåre I Birkeland, Johan Bodegard, Amitava Banerjee, et al.
Diabetes, Obesity & Metabolism|November 25, 2020
How many people with type 2 diabetes fulfil the eligibility criteria for randomized, controlled trials of insulin glargine 300 U/mL in a real-world setting?Dídac Mauricio, Jukka Westerbacka, Charlie Nicholls, et al.
Diabetes, Obesity & Metabolism|November 25, 2020
Weight-loss response to naltrexone/bupropion is modulated by the Taq1A genetic variant near DRD2 (rs1800497): A pilot studyJamie A Mullally, Wendy K Chung, Charles A LeDuc, et al.
Diabetes, Obesity & Metabolism|November 25, 2020
Dose-dependent accumulation of glucose in the intestinal wall and lumen induced by metformin as revealed by 18 F-labelled fluorodeoxyglucose positron emission tomography-MRIJun Ito, Munenobu Nogami, Yasuko Morita, et al.
Diabetes, Obesity & Metabolism|November 3, 2020
Risk of developing diabetes in patients with atrial fibrillation taking non-vitamin K antagonist oral anticoagulants or warfarin: A nationwide cohort studyHuei-Kai Huang, Peter Pin-Sung Liu, Shu-Man Lin, et al.
Diabetes, Obesity & Metabolism|November 3, 2020
Patients' preferences for once-daily oral versus once-weekly injectable diabetes medications: The REVISE studyKristina Boye, Melissa Ross, Reema Mody, et al.
Diabetes, Obesity & Metabolism|February 11, 2020
Cardiovascular and kidney outcomes of linagliptin treatment in older people with type 2 diabetes and established cardiovascular disease and/or kidney disease: A prespecified subgroup analysis of the randomized, placebo-controlled CARMELINA® trialMark E Cooper, Julio Rosenstock, Takashi Kadowaki, et al.
Pageof 630